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Understanding the cellular basis of neurological disorders have advanced at a slow pace,
especially due to the extreme invasiveness of brain biopsying and limitations of cell
lines and animal models that have been used. Since the derivation of pluripotent stem
cells (PSCs), a novel source of cells for regenerative medicine and disease modeling
has become available, holding great potential for the neurology field. However, safety for
therapy and accurateness for modeling have been a matter of intense debate, considering
that genomic instability, including the gain and loss of chromosomes (aneuploidy), has
been repeatedly observed in those cells. Despite the fact that recent reports have
described some degree of aneuploidy as being normal during neuronal differentiation and
present in healthy human brains, this phenomenon is particularly controversial since it
has traditionally been associated with cancer and disabling syndromes. It is therefore
necessary to appreciate, to which extent, aneuploid pluripotent stem cells are suitable
for regenerative medicine and neurological modeling and also the limits that separate
constitutive from disease-related aneuploidy. In this review, recent findings regarding
chromosomal instability in PSCs and within the brain will be discussed.
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INTRODUCTION
Mitotic neural progenitor cells (NPCs) are frequently aneuploid
(Rehen et al., 2001) and, albeit neurogenesis is accompanied by
massive cell death (Blaschke et al., 1996) which may reduce brain
aneuploidy (Yurov et al., 2005; Mosch et al., 2007), a significant
proportion remains and generates long-life lasting mature aneu-
ploid neurons (Rehen et al., 2005) capable of integrating to the
brain circuitry (Kingsbury et al., 2005). The biological effects
of aneuploidy in the brain are still a matter of speculation, but
it possibly serves as a diversity generation mechanism (Rehen
et al., 2001, 2005; Kingsbury et al., 2006; Iourov et al., 2006).
Loss of heterozygosity (LOH) produced by chromosomal loss can
alter gene expression without affecting cell proliferation and sur-
vival (Kaushal et al., 2003). In a neuronal network, connection
of aneuploid cells to euploid cells is expected to confer extra
variability contributing to interpersonal uniqueness (Kingsbury
et al., 2005; Muotri and Gage, 2006), however, a narrow bound-
ary between aneuploidy as a diversifier agent in healthy brain and
as a prompter of diseases may exist since this phenomenon has
been repeatedly observed in pathological conditions.
Although neurological disturbances have been known for cen-
turies, they remain poorly understood, partially due to limita-
tion of available experimental approaches (post-mortem brains,
immortalized human cells or animal models), and treatments
are still unsatisfactory (Lukiw, 2012; Miyamoto et al., 2012).
Therefore, development and validation of novel in vitro models
may accelerate knowledge directed to neurological disturbances.
Pluripotent stem cells (PSCs) have the potential to self-renew and
generate cells from the three germ layers, been largely considered
as a promising source for modeling and drug screening. The main
PSCs are embryonic stem cells (ESCs), which are derived from
the inner cell mass of blastocyst, and induced pluripotent stem
cells (iPSCs), generated through induction of pluripotency fac-
tors expression in somatic cells (Takahashi et al., 2007). While
ESCs represent the natural PSCs prototype, iPSCs have the advan-
tage to overcome ethical and (in principle) incompatibility issues
inherent to its embryonic origin as well as to provide a source
for disease modeling that cannot be tracked by preimplantation
genetic diagnosis (PGD).
Many diseases are associated to genetic components and var-
ious alleles can predispose to the same pathological outcome.
Patient-specific somatic cells reprogrammed into iPSCs preserve
its particular genetic background, providing an alternative to
study diseases in a non-invasive manner, without prior knowl-
edge of disorders-associated genes. Moreover, they possess the
unique capacity to recapitulate development in an embryo-like
fashion, representing an excellent source to study neurogenesis
and neurodevelopmental diseases. Indeed, several studies have
described cells differentiated from iPSCs able to recapitulate many
aspects of distinct disorders, demonstrating their applicability
for disease modeling (Ebben et al., 2011; Grskovic et al., 2011;
Kunkanjanawan et al., 2011; Saha and Hurlbut, 2011; Tiscornia
et al., 2011; Oh et al., 2012). However, to serve as a source for cell
therapy and to model diseases reliably, PSCs need to be safe and
preserve phenotypic aspects observed during development. The
description of genomic modifications in PSCs, especially in the
artificially generated iPSCs, gave rise to an intense debate on their
usefulness (Panopoulos et al., 2011; Pera, 2011; Ross et al., 2011).
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Genomic modifications can result in genomic instability and
aremeasured at different resolution levels. Such modifications are
depicted as aneuploidy, chromosome rearrangements, copy num-
ber variation (CNV) and single nucleotide polymorphism (SNP).
Aneuploidy involves loss or gain of one or more chromosomes
compared to the original species’ set. In contrast, other modi-
fications mentioned are confined to portions of chromosomes.
More specifically, while rearrangements spatially reorganize genes
and/or their regulatory elements, CNVs consist of duplication or
deletion of DNA portions, whereas SNPs are single nucleotide’s
alterations. Such changes can have drastic effects for cells, altering
gene dosage and integrity.
Genome alterations (particularly aneuploidy) have been
largely correlated with cancer, malformation, miscarriage and
other pathologies (Duesberg et al., 2006; Conrad et al., 2010;
Lebedev, 2011; Coschi and Dick, 2012), although their participa-
tion in evolutionary processes is well recognized (Cooper et al.,
2004; Nguyen et al., 2008; Pavelka et al., 2010; Stenberg and
Larsson, 2011). As mentioned previously, such variations have
been suggested to contribute to diversity in the healthy brain
(Kingsbury et al., 2005; Rehen et al., 2005; Westra et al., 2008)
and evidences also indicate that PSCs are not homogeneously
euploid, which suggest that chromosomal mosaicism is inherent
to these cells (Peterson et al., 2011), probably as consequence of
their singular cell cycle (White and Dalton, 2005).
Aneuploidy as a natural phenomenon in healthy individuals
is a relatively new concept. Up to now, only a few tissues have
been demonstrated to tolerate aneuploidy, and its usual associ-
ation with pathogenic contexts generates the need to distinguish
normal from disease-related gain and loss of chromosomes. Given
the existence of aneuploidy in PSCs, their suitability as a source
for cell therapy and modeling will be considered. Moreover, a
brief description of aneuploidy in mental disorders will be under-
taken in an attempt to clarify the boundaries separating normal
from disease-related chromosomal mosaicism.
ANEUPLOIDY IN MENTAL DISORDERS
From all genomic modifications, ploidy is particularly drastic
since gains or losses of whole chromosomes abruptly alter the
dosage of hundreds of genes in a cell, leading to possible imbal-
ances in critical proteins. LOH, described as the change of a
heterozygous state to a homozygous state, can arise after loss of
a whole chromosome and have severe effects. Monosomy and
trisomy of almost all chromosomes in the embryo are lethal.
Trisomy 13, 18, and 21 are the only non-sexual-chromosome
aneuploidies that allow full term pregnancy, and severity of phe-
notypes depends on the incidence of the abnormality among
their cells. Interestingly, these chromosomes contain the fewest
protein-coding genes (Torres et al., 2008). Therefore, different
types and frequencies of mosaic aneuploidy in individuals might
havemore or less tolerable effects for cell function and adaptation
under stress conditions.
Mosaic aneuploidy has been described as a normal occur-
rence in adult and developing brains (Rehen et al., 2005; Yurov
et al., 2005, 2007a) but it has most traditionally been associated
with pathologies. It has therefore been postulated that aneu-
ploidy may be harmless or detrimental to proper functioning of
CNS depending on its level. In fact, a 2 fold random aneuploidy
and a 4 fold specific chromosome 21 aneuploidy increase was
reported in ataxia telangiectasia’s (AT) and Alzheimer disease’s
(AD) patients brains, respectively (Iourov et al., 2009b). As shown
in Table 1, AT brain aneuploidy encompasses both gain and loss
of almost all chromosomes, whereas AD brains display preferen-
tial unbalance of chromosome 21 and chromosome 17 (mostly
gain). Importantly, amyloid precursor gene, responsible for Aβ
peptide production, is localized at chromosome 21. Analogously,
tau gene, which encodes a component of neurofibrillary tangles in
AD, is located on chromosome 17, reinforcing the contribution of
such excessive chromosomal dosages for AD etiology.
Schizophrenic patients were also described to have
X-aneuploidy in a frequency 4–6 higher than normal sub-
jects in blood cells (Delisi et al., 1994; Bassett et al., 2000).
Additionally, chromosome 1 aneuploidy is three times higher in
schizophrenic brains than in normal brains (Table 1). Notably,
specific genes such as DISC1 (disrupted in schizophrenia 1) and
neuregulin 1, localized at chromosome 1, have been associated
with the disorder (Sullivan, 2008). Moreover, a cohort of autistic
children was identified to display increased frequency of aneu-
ploidies involving chromosomes 9, 15, 16, 18, and X in peripheral
blood lymphocytes (Yurov et al., 2007b). Nonetheless, only few
patients show augmented levels of chromosomal mosaicism in
the brain, suggesting that aneuploidy may just contribute to a
certain proportion of cases.
Another argument favoring the “aneuploidy dosage” hypoth-
esis is based on the fact that Down’s syndrome individuals with
distinct levels of trisomic 21 cells vary from normal development
(Verresen et al., 1964; Kohn et al., 1970) to mild (Ringman et al.,
2008) or severe developmental delay (Richards, 1969). This indi-
cates that frequency and type of aneuploidymight dictate whether
a tissue will stay healthy or become diseased.
Table 1 | Aneuploidy in healthy and neurological disordered brains.
Chromosomes % Aneuploidy (loss, gain)
Healthy AT AD Schizo
brain
1 0.5 (0.3, 0.2) 2.8 (1.7, 1.1) 0.7 (0.3, 0.4) 1.8 (0.9, 0.9)
7 0.7 (0.3, 0.4) 1.5 (0.6, 0.8) NA NA
8 1.0 (0.3, 0.7) 2.8 (0.8, 2.0) NA NA
9 1.2 (0.5, 0.7) 1.3 (0.6, 0.7) NA NA
11 0.8 (0.4, 0.3) 3.1 (1.5, 1.5) 1.1 (0.7, 0.4) NA
16 0.7 (0.1, 0.6) 2.8 (0.4, 2.5) NA NA
17 2.2 (0.4, 1.8) 2.4 (1.2, 1.2) 7.7 (0.5, 7.2) NA
18 0.9 (0.5, 0.4) 2.5 (1.2, 1.2) 1.0 (0.5, 0.4) 0.5 (NR, 0.5)
21 2.5 (1.3, 1.3) NA 10.7 (4.1, 6.6) NA
X 0.7 (0.3, 0.4) 1.8 (0.3, 1.5) 1.9 (0.7, 1.2) 1.2 (NR, 1.2)
Y 0.2 (0.1, 0.1) 0.6 (0.0, 0.6) NA NA
NR, Not reported; NA, Not available; AT, Ataxia telangiectasia; AD, Alzheimer’s
disease; schizophrenia (schizo). Mean aneuploidy was calculated based on
Rehen et al. (2005); Mosch et al. (2007); Yurov et al. (2008); Iourov et al. (2009b)
for healthy brain, (Iourov et al., 2009a,b) for AT, (Mosch et al., 2007; Iourov et al.,
2009b) for AD and (Yurov et al., 2001, 2008) for schizophrenia.
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But how could, then, the normal limit of tolerable aneuploidy
be surpassed? In a normal scenario of neurogenesis, both overpro-
duction and clearance of neural progenitors occur (Blaschke et al.,
1996) concomitantly with aneuploidy (Sartore et al., 2011).While
neutral and/or benign aneuploidies would persist, giving rise to
genetic mosaicism in the brain, some results have suggested that
detrimental aneuploidies would be cleared (Rehen et al., 2001;
Kaushal et al., 2003). Considering this situation, an inefficient
clearance could lead to an excessive accumulation of aneuploid
cells in some neurological diseases (Figure 1). In Atm −/− mice,
gain and loss of chromosomes are increased in embryonic NPCs
and adult cerebral cortex, suggesting that clearance of aneuploid
NPCs by apoptosis is deficient in these mice. Likewise, as men-
tioned, AT human brains present elevated aneuploidy (Iourov
et al., 2009a). Another example of a neurological disorder with
excessive aneuploidy is mosaic variegated aneuploidy syndrome
(MVA), a disease that can be caused by BUB1B mutations, which
leads to impaired mitotic checkpoint and aneuploidy (Bohers
et al., 2008; Suijkerbuijk et al., 2010).
Identifying chromosomal abnormalities associated with neu-
rological disorders may help locating and predicting genes
involved in those complex diseases. However, the analysis of gain
and loss of chromosomes in post-mortem brain may pose some
limitations, as it resembles the final-stage of the disease, leading
to misinterpretations due to secondary causes, such as chronic
use of an antipsychotic or aging itself. Likewise, animal models
cannot correctly predict human genes participating in diseases
due to lack of architectural chromosomes equivalence. In this
regard, models such as iPSCs, which allow to recapitulate neu-
rodevelopmental stages and correctly track genetic changes, will
certainly have greater application in understanding the etiology
of unknown-causative brain disorders.
ANEUPLOIDY IN PLURIPOTENT STEM CELLS
It is now clear that contrarily to what was believed after its deriva-
tion, many PSCs exhibit some degree of aneuploidy (Peterson
et al., 2011). Even though first considered solely as a hurdle
for the organisms, aneuploidy is starting to be considered as a
normal phenomenon in certain cases. Indeed, random mosaic
aneuploidy is frequent in embryos at cleavage stage (Munne et al.,
1994; Vanneste et al., 2009; Yurov et al., 2009; Iourov et al., 2010;
Robberecht et al., 2010; Mantzouratou and Delhanty, 2011; Van
Echten-Arends et al., 2011; Nagaoka et al., 2012; Vanneste et al.,
2012) independently of maternal age (Delhanty et al., 1997; Baart
et al., 2006). Despite the fact that many of those mosaic aneu-
ploid embryos result in abortion (Warburton et al., 1978; Philipp
et al., 2003; Lebedev, 2011), later-phase euploid embryos previ-
ously diagnosed as aneuploid are frequent (Li et al., 2005), which
indicates their ability to cope with this phenomenon. Actually,
because the majority of cells in the preimplantation embryo give
rise to the placenta, most aneuploid cells turn out to be located
in this structure, limiting aneuploidy’s contribution to the fetal
body. A possibility is that in the ectotrophoblast destined to
become the placenta, early aneuploidy generation would help to
enhance invasiveness, assisting embryo to implant (Weier et al.,
2006), which is in agreement with its natural occurrence dur-
ing embryogenesis. In fact, chromosomal mosaicism might even
have been underestimated since PGD only analyses a few chromo-
somes from one of a total of 6–10 blastomeres and several works
corroborate the deficiency of PGD single-blastomere analysis in
FIGURE 1 | Aneuploidy during neurogenesis is followed by a clearance of excessive aneuploid cells. If there is a defective clearance or an overproduction
of aneuploid cells, an increased frequency of aneuploidy might contribute to CNS pathogenesis.
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detecting chromosomal mosaicism (Wells and Delhanty, 2000;
Baart et al., 2006; Coulam et al., 2007; Ambartsumyan and Clark,
2008; Vanneste et al., 2009).
Despite increasing evidence of a normal occurrence of aneu-
ploidy before derivation, not all PSCs aneuploidies seem to be
products of in vivo selection. Indeed, since PSCs derivation, clonal
genomic modifications were described to contribute to culture
adaptation constituting a limitation for their use. Studies indicate
that mechanical disaggregation of colonies tends to preserve chro-
mosomal stability (Mitalipova et al., 2005; Catalina et al., 2008;
Rashid et al., 2010) probably due to preservation of cell-cell con-
tact and paracrine signaling necessary for their survival (Moogk
et al., 2010). Absence of such signals during single-cell splitting
could represent a pressure favoring the ascendance of aneuploid
cells adapted to the new situation. Increased passaging was also
correlated with genomic modifications (Enver et al., 2005; Maitra
et al., 2005; Baker et al., 2007; Mayshar et al., 2010; Laurent
et al., 2011; Ross et al., 2011), while low levels of O2,compatible
with in vivo condition, were found to favor genome integrity
in ESCs cultures (Forsyth et al., 2006; Lim et al., 2011). Such
descriptions are compatible with cell adaptation to stressful and
unnatural conditions (long term self-renewal and high oxidative
stress in vitro), once such aneuploidies involve recurrent gain of
the same chromosomes and tend to overcome cell culture (Amps
et al., 2011). Contrastingly, no correlation could be established
between basal aneuploidy presence and any particular culture
condition, including media, supplements or substrate as reported
in a recent study from Peterson and coworkers (2011). This
suggests that intrinsic conditions, other than culture conditions
per se, contribute to aneuploidy as well (Figure 2).
The reason why all PSCs were previously believed to be homo-
geneously euploid probably relies on both reduced number of
metaphases analyzed (Lin et al., 2007; Mai et al., 2007; Itoh et al.,
2011) and acceptance that hypoploidy was a technical artifact as
stated by standard cytogenetic books (Barch et al., 1997; Meisner
and Johnson, 2008; Zheng and Dean, 2009). Many papers report-
ing euploid genomes have outsourced karyotyping (Lee et al.,
2009; Chamberlain et al., 2010; Ananiev et al., 2011; Mitne-Neto
et al., 2011; Seibler et al., 2011; Sheridan et al., 2011), counted only
20–50 (Lin et al., 2007; Mai et al., 2007; Itoh et al., 2011) or omit-
ted the number of counted cells (Ye et al., 2009; Carvajal-Vergara
et al., 2010; Cheung et al., 2011; Jin et al., 2011; Liu et al., 2011;
Tolar et al., 2011), probably underscoring low-level mosaic aneu-
ploidies, since at least 100 metaphases were counted by Peterson
and colleagues to detected 3% aneuploidy (Peterson et al., 2011).
Moreover, 18–35% of cultured cells from 6 distinct PSCs lines
displayed random aneuploidy affecting different chromosomes at
low rates (Peterson et al., 2011). The absence of specific recur-
rence suggests that low-level mosaic aneuploidy must not confer
selective advantage to cells, being therefore unrelated to culture
adaptation. Furthermore, it is noteworthy that, like in healthy
liver and brain, chromosome losses account formost aneuploidies
observed in PSCs (Peterson et al., 2011), contrasting with a pre-
dominance of chromosomal gains inmental disorders and cancer.
Importantly, results were confirmed by FISH (interphase nuclei),
which discards the possibility of technical artifacts to explain loss
of chromosomes. Besides, constitutive PSCs mosaic aneuploidy
is consistent with and could help explaining the observed phe-
notypic and functional heterogeneity within cultures (Chambers
et al., 2007; Singh et al., 2007; Graf and Stadtfeld, 2008; Hayashi
et al., 2008; Chin et al., 2009; Hough et al., 2009).
In vivo, chromosomal mosaicism might be a diversifying agent
conferring an advantage for embryo survival in certain conditions
(i.e., malnutrition during pregnancy, atrophied endometrium,
FIGURE 2 | Aneuploidy in pluripotent stem cells. Low-level aneuploidy
affecting multiple chromosomes may be a residual feature of cells from the
inner cell mass. In culture, cells are under selective environment and some
kinds of aneuploidy may benefit from improved self-renewal, proliferation or
anti-apoptotic properties. As a result, cells carrying such aneuploidy may
overcome the culture.
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women under medication, etc). Therefore, it is probable that low-
level stochastic chromosomal aneuploidy (especially losses) is well
tolerated and contributes to enhanced capacity to overcome envi-
ronmental changes and to respond contrastingly (self-renewal or
specialization in distinct cell types) to differentiation stimuli. On
the other hand, gain of chromosomes seem to have an unfavorable
outcome in somatic cells since they tend to disappear follow-
ing differentiation (Mantel et al., 2007), decrease in later-stage
embryos (Evsikov and Verlinsky, 1998), be confined to placenta
(Kalousek, 1993; Gonzalez-Merino et al., 2003) or, in worst cases,
result in abortion or malfunctioning. In addition, chromoso-
mal mosaicism has also been described within the developing
human brain (Yurov et al., 2007a) with no clear correlation with
neurological diseases.
ARE INDUCED PLURIPOTENT STEM CELLS PRONE TO
ANEUPLOIDY?
Somatic cell origin of iPSCs raised the concern that they would
displaymore genomemodifications than ESCs, as cells from older
individuals, subjected to environmental mutagenic influences,
would have greater chance to accumulate DNA abnormalities.
Although iPSCs harboring DNA changes originated in somatic
cell progenitors have been described (Mayshar et al., 2010; Gore
et al., 2011; Ji et al., 2012), the inner cell mass—as the origin
of ESCs—commonly exhibits aneuploidy as well (Munne et al.,
1994; Vanneste et al., 2009; Mantzouratou and Delhanty, 2011).
It is unclear whether the frequency of genomic modifications in
somatic cells is higher than in the inner cell mass, although in
mice, somatic cells’ mutation-rate seems to be superior to that
of ESCs (10−4 compared to 10−6, respectively) (Cervantes et al.,
2002).
Reprogramming methods used to create iPSCs has also been
a matter of concern. Lenti or retrovirus-derived iPSCs were
generally considered as genomic-instability-prone, since random
DNA integration of pluripotency factors could disrupt genes
involved in tasks such as DNA repair and cell cycle. Undoubtedly,
reprogramming represents a stress to cells, which may facilitate
genomic abnormalities to arise. However, since genomic instabil-
ity is seen in reprogrammed cells regardless of employed repro-
grammingmethod, it might rather reflect the enforced phenotype
change imposed to somatic cells than the chosen technique (Gore
et al., 2011; Taapken et al., 2011). Paired comparative studies of
iPSCs reprogrammed from the same somatic cell type, using dif-
ferent approaches, are required in order to clarify the contribution
of reprogramming methods to genome instability.
Qualitatively, only few chromosomal changes seem unique to
either ESCs or iPSCs. When scrutinizing a table from a recent
review (Martins-Taylor and Xu, 2012), which compares chromo-
somal macroscopic abnormalities between human ESCs (hESCs)
and human iPSCs (hiPSCs) after prolonged culture, most alter-
ations were common to both types of cells (i.e., trisomy of the X,
12, 8, 20q, and amplification of 17q, 20q11.21), while a minority
was exclusively detected in either hESCs or hiPSCs. Such observa-
tions indicate that: (1) some genomic modifications recurrently
(and clonally) seen must confer adaptive advantage to both cell
types; (2) the reprogramming process is not responsible for a
certain portion of the instability seen in hiPSCs (since hESCs,
which have not been reprogrammed, also display some identical
instability signatures); (3) some modifications could be linked to
the specific pluripotent cellular type (i.e., trisomy 17, deletion of
18q12.1 to hESCs and deletion of 17q21.1 and 8q24.3 to hiPSCs,
for instance); (4) other genomic alterations might not be observed
due to their detrimental effect on pluripotency or survival of the
cells [i.e., many aneuploidies, for instance, result in diminished
fitness of cells or whole organisms (Sheltzer and Amon, 2011)].
Finally, some types of genomic modifications acquired during
reprogramming or early passages have been reported to disappear,
resulting in similar CNV levels among hESCs and hiPSCs at later
passages (Hussein et al., 2011), indicating that CNV levelsmust be
similar in both PSCs types. Reinforcing these findings, Taapken
and coworkers (2011) had not observed differences in the inci-
dence of abnormal karyotype (ESCs: 12.9% and iPSCs: 12.5%)
when comparing 40 ESCs and 219 iPSCs lines from 29 differ-
ent laboratories. Nonetheless, additional large-scale studies with
ESCs and iPSCs cultured under equivalent conditions are needed
to conclude if frequency and type of other genomic modifications
differ in these two populations.
THE BASIS OF ANEUPLOIDY IN PLURIPOTENT STEM CELLS
Several studies attempted to elucidate the molecular mechanisms
causing imbalances in the chromosomal content of proliferative
cells. Initially, themolecularmechanisms driving aneuploidy were
explored in cancer cell lines, most likely due to the high fre-
quency of chromosomal instability (CIN) associated with tumor
phenotype. The “initial suspects” were molecules involved in
the mitotic checkpoints. In fact, inactivation of mitotic check-
points was shown to produce aneuploidy in different biological
scenarios (Kops et al., 2005). It is more likely, however, that
aneuploidy can arise by a combination of factors. For example,
chromatid fragments can be the result from unrepaired DNA
breaks. Chromosomes loss or gain can outcome fromhypomethy-
lation of centromeric DNA, defects in kinetochore or assembly
proteins, as well as dysfunctional spindle and anaphase check-
point genes (Yang et al., 2003; Iourov et al., 2006; Fenech et al.,
2011).
Important tumor suppressors are central for many aspects
of cell life, including control of proliferation, cell death, cell
cycle arrest and chromosomal stability. P53 is one of the
most studied tumor suppressors, and not surprisingly its
pathway has been implicated in aneuploidy. The absence of
P53 allows polyploid cells to proliferate and generate unsta-
ble aneuploid progeny (Holland and Cleveland, 2009; Talos
and Moll, 2010). In ESCs, p53 maintains genetic stability
through elimination of DNA-damaged ESCs from the replicative
ESCs pool by directly suppressing the expression of transcrip-
tion factor Nanog, which is necessary for pluripotency (Xu,
2005).
Another important gene for chromosomal stability is
retinoblastoma (Rb-1). Stable inactivation of Rb leads to over-
expression of mitotic arrest deficient 2 (Mad2), which induces
aneuploidy (Hernando et al., 2004). Among Rb pathway’s
targets, changes in the expression of genes encoding proteins
responsible for progression through mitosis, mitotic checkpoints
and centrosome homeostasis, such as Plk1, Brca1, Aurora
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A/Stk6, Mad2 and Securin, were observed after Cre-mediated
inactivation of Rb (Iovino et al., 2006). Little later, Iovino and
colleagues demonstrated that Aurora A and Centrosome Protein
A (CENP-A) might be necessary for the centrosome duplication,
micronuclei formation and for the generation of aneuploidy
induced by Rb-depletion (Amato et al., 2009a,b).
In 2010, independent studies confirmed the role of Rb in the
regulation of CIN in vivo and in several cell types such as ESCs
(Coschi et al., 2010; Manning et al., 2010; Van Harn et al., 2010),
after observing a defective centromeric localization of Condensin
II in Rb-depleted cells (Coschi et al., 2010; Manning et al., 2010).
Altogether, these findings confirm that Rb plays a direct role in the
maintenance of genomic stability by regulating the expression of
specific genes important for chromosomes attachment to spindle,
centrosome replication and checkpoints. Finally, Rb is critical, in
haploinsufficiency, for the maintenance of chromosome stabil-
ity in mouse embryonic stem cells (mESCs) (Zheng et al., 2002).
Whether p53 and/or Rb deficiency is responsible for the natural
aneuploidy observed in cultured stem cells (Peterson et al., 2011)
remains to be determined.
In pluripotent cells, reduced time is dedicated to G phases,
probably reflecting initial embryo demand for rapid cell accu-
mulation (White and Dalton, 2005; Ruiz et al., 2011) before
transcription is activated (Braude et al., 1988). The abbreviation
of checkpoint-containing phases might propitiate aneuploidy.
Although the atypical S/M-predominant cell cycle is present in
human pluripotent stem cells (hPSCs) (White and Dalton, 2005;
Momcilovic et al., 2010), information on checkpoints’ function-
ality is insufficient to draw any definitive conclusion (Becker et al.,
2007;Mantel et al., 2007;Momcilovic et al., 2009, 2010). However,
evidences from mESCs suggest checkpoint disruption is a fea-
ture of any highly proliferating cell with self-renewal capability,
including hPSCs. At the G1 checkpoint, mESCs progress into S
phase despite nucleotides depletion and DNA injuries (Aladjem
et al., 1998; Hong and Stambrook, 2004), partially due to ineffi-
cient p53 nuclear translocation (Aladjem et al., 1998) and Chk2
sequestration in centrosomes (Hong and Stambrook, 2004).
Added to that, mitotic-spindle checkpoint, which helps
to maintain chromosomal integrity during cell division, is
uncoupled from apoptosis as microtubule-disrupted hESCs can
progress through cell cycle even in the presence of mitotic-
spindle-detached chromosomes (Mantel et al., 2007). Moreover,
the decatenation checkpoint, responsible for preventing cell cycle
progression in the presence of entangled chromosomes, is ineffi-
cient in mESCs causing severe aneuploidy (Damelin et al., 2005).
Finally, mESCs self-renewal ability seems to depend on intrinsic
nucleolin-mediated p53-pathway suppression (Yang et al., 2011).
Since p53 pathway is essential for genomic integrity mainte-
nance, self-renewable cells are naturally expected to exhibit some
aneuploidy.
Given the unlimited nutrition at early development stages,
generating new PSCs represents a better strategy than correct-
ing damages to contain damage spread (Li and Huang, 2010).
Accordingly, in cases in which genomic instabilities are excessively
abundant or detrimental, cells might undergo differentiation
(Ambartsumyan and Clark, 2008; Ruiz et al., 2011) or apoptosis
(Momcilovic et al., 2010). Differentiation in developing embryos
would restore cell cycle (Aladjem et al., 1998) and checkpoints
(Damelin et al., 2005; Egozi et al., 2007; Mantel et al., 2007;
Momcilovic et al., 2010) as well as induce many cells to exit cell
cycle, selecting against propagation of most genome modifica-
tions. Alternatively, intrinsic PSCs loose checkpoints would allow
some aneuploidies to persist during early development, while cells
are still pluripotent.
CONCERNS REGARDING ANEUPLOIDY FOR CELL THERAPIES
Cell therapy represents the most defiant and desired application
envisioned for PSCs. While ESCs use would necessitate immuno-
suppressive treatment coupled to compatible matched cells from
a donor bank, iPSCs would in priori exempt immunosuppressive
treatment but, in the other hand, demand very precise gene-
targeted correction when treating monogenetic diseases of known
background.
First, aneuploidy represents a challenge for PSCs safety because
the large amount of cells required for such applications is usu-
ally achieved by prolonged culture time. Long term cultivation
favors aneuploidy (and other genetic modifications) in any cell
type, and this has been clearly documented in PSCs (Enver et al.,
2005; Maitra et al., 2005; Baker et al., 2007; Mayshar et al.,
2010; Ross et al., 2011). Since pluripotent cells only exist tran-
siently in vivo, giving rise to more committed cell lines following
embryo development, forced maintenance of ESCs and iPSCs in
the unnatural culture conditions for extended time is expected
to allow accumulation of undesired and/or high level aneuploidy
compromising their safety for cell therapy. Accordingly, cancer-
related genes were identified in all chromosomes (12, 17, 20, X),
whose imbalances are recurrently associated with culture adapta-
tion (Draper et al., 2004; Maitra et al., 2005; Baker et al., 2007;
Hovatta et al., 2010). Notably, teratomas from culture-adapted
hESCs were described as more aggressive and less differentiated
than teratomas from diploid hESCs (Herszfeld et al., 2006; Yang
et al., 2008; Blum and Benvenisty, 2009). Moreover, as PSCs are
teratogenic-prone, efficient differentiation protocols followed by
very rigorous purification must be developed before cells are
ready for human tests.
Since PSCs differentiation protocols are time-consuming and
suboptimal, long-term culture of NPCs could be proposed as a
solution to accelerate neurons availability. Nonetheless, continu-
ous NPCs culturing increases chances of DNA changes accumu-
lation as well as drive them to senescence. In fact, aneuploidy’s
increase after as short as 3 weeks could be detected in human cul-
tured fetal NPCs (Yurov et al., 2005; Sareen et al., 2009). In one of
these works (Sareen et al., 2009), trisomy of chromosomes 7 and
19 conferring growth advantage to the NPCs could be observed,
representing a potential risk for tumor development following
transplantation.
Indeed, an AT patient transplanted with fetal neural stem cells
was diagnosed, 4 years later, with a brain tumor of non-host ori-
gin (Amariglio et al., 2009), highlighting the risks of stem cell
“left-over” in differentiated cells to be used in humans. Although
chromosomal stable fetuses seem to be selected for isolation of
these cells, details of karyotype analyses after culture were absent.
One could not discard transferred aneuploid neural stem cells
as a source of tumor cells. In this regard, the paucity of data
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comparing aneuploidy levels among brain regions makes it even
more difficult to predict the outcomes of applying neurons with
aneuploidy acquired in vitro in therapy.
Concerning senescence, recurrent translocation of chromo-
some 1 q arm, previously associated with hematologic malignan-
cies and pediatric brain tumors, allowed ESCs-derived NPCs to
bypass it. However, such NPCs were unable to integrate into rat
brains (Varela et al., 2012), reinforcing the negative impact of
certain DNA changes on cell therapy. Finally, even though ane-
uploidy does not automatically imply in differentiation hurdles
(Plaia et al., 2006), some were shown to hinder pluripotent cells
differentiation to desired cell types. HESCs carrying deletion of
7q and an isochromosome 12 failed to express some markers of
germ layers when differentiated into embryoid bodies (EB) and
could not form teratomas in vivo (Imreh et al., 2006); ESCs with
duplications of 1p32 and 1p36 were biased to differentiate to
ectoderm, while their karyotypic normal counterparts tended to
differentiate into mesoderm and endoderm (Yang et al., 2010),
and trisomic 12 ESCs had enhanced potential to be differenti-
ated in renal cells (Gertow et al., 2007). Detailed characterization
of phenotypic changes related to proliferation, apoptosis signal-
ing, immunogenicity and differentiation capacity conferred by all
sets of aneuploidies are therefore mandatory before PSCs can be
adopted for cell therapy.
ANEUPLOID iPSCs AND NEURAL DISEASE MODELING
iPSCs offer the possibility to study diseases with genetic con-
tribution for which the exacts DNA markers have not yet been
established, taking advantage of somatic cells from diagnosed
individuals. These cells are specially promising for the study of
diseases displaying spectral phenotypes, in which each individ-
ual presents slightly different symptoms and treatment response
patterns, complicating the choice of treatment. Finally, culture-
dish format makes of iPSCs an extremely simple and convenient
system to use. In spite of all these advantages, since PSCs have
been proposed to exist mainly as aneuploid mosaics, whether
aneuploid iPSCs will correctly reflect diseases unrelated to chro-
mosomal abnormalities remains to be determined.
In this regard, certain types/proportion of aneuploidy should
not represent an issue for studying central nervous system dis-
eases, considering that mosaic aneuploidy is constitutive to the
brain (Kingsbury et al., 2005, 2006; Rehen et al., 2005). Actually,
aneuploidy seems to be a natural phenomenon during neuro-
genesis. In an attempt to elucidate whether aneuploidy takes
place during neural fate patterning, Sartore et al. used both ESCs
and iPSCs to recapitulate neurogenesis. Cells differentiated into
NPCs and neurons exhibited heightened levels of aneuploidy
after cellular commitment, especially chromosome loss, consis-
tently with in vivo observations (Rehen et al., 2001; Kaushal et al.,
2003; Westra et al., 2008). Also, displaced interactions between
kinetochores and microtubules were hypothesized as a plausible
driver of aneuploidy, since reduced levels of survivin, a pro-
tein participating in mitotic-spindle-microtubules anchorage to
kinetochores and spindle assembly checkpoint (Lens et al., 2003;
Saito et al., 2008; Sun et al., 2009), was found in NPCs (Sartore
et al., 2011) together with previous findings of inefficient check-
points (Damelin et al., 2005) and amplified centrosomes (Yang
et al., 2003). The fact that aneuploidy has indeed been reported
to increase during neuronal differentiation (Sartore et al., 2011)
makes it rather a prerequisite for modeling diseases known to
affect neurons.
Although information regarding iPSCs ploidy-status used to
model diseases is usually absent or underestimated, no deficit in
their differentiation capacity has been reported, and innumer-
ous studies have achieved to recapitulate one or more features
distinctive of pathological conditions using iPSCs (see below).
Corroborating their value as models and drug-testing plat-
form, iPSCs-derived neurons from Rett’s syndrome displayed
MeCP2-decreased levels typical of the disease that could be
restored following treatment with aminoglycoside antibiotics
(Marchetto et al., 2010); iPSCs-derived neurons from patients
with Alzheimer’s disease showed elevated Aβ42–Aβ40 ratio,
phospho-Tau and active GSK-3β, all reduced when treated with
β- or γ-secretase inhibitor and modulator (Yagi et al., 2011;
Israel et al., 2012); iPSCs-derived neurons from schizophrenic
patients exhibited superior amounts of reactive oxygen species,
reverted after valproic acid treatment (Paulsen et al., 2011) and
reduced neuronal connectivity improved after loxapine admin-
istration (Brennand et al., 2011); motor neurons differentiated
from spinal muscular atrophy’s iPSCs had diminished expres-
sion of full length SMN-RNA, and the accumulation of SMN
nuclear aggregates could be observed after exposure to valproic
acid and tobramycin (Ebert et al., 2009). These studies demon-
strate that, regardless of aneuploidy, iPSCs are capable to mirror
at least some important aspects of chromosomal syndromes and
adult diseases with genetic contribution. Furthermore, because
different drugs were successfully used to revert disease hallmarks
in iPSCs-derived models, their application for pharmacological
screening is extremely promising.
Despite its indisputable value to achieve diseases better under-
standing and treatment, it is important to keep in mind that
iPSCs display some limitations in modeling diseases. The first
and more critical caveat relies on the fact that differentiation
of iPSCs occurs in a two dimensional isolated environment, in
the absence of diverse tissue-partners cells, structures and stimuli
that may participate in a decisive way in disease establishment or
maintenance. This would preclude the complete understanding
of disorders and probably hamper high efficiency drugs develop-
ment. Glial cells, for instance, have been suggested to participate
in schizophrenia (Bernstein et al., 2009; Takahashi et al., 2011;
Walterfang et al., 2011), as well as estrogen imbalance (Riecher-
Rossler and Kulkarni, 2011). Likewise, late onset mental diseases
are still difficult to depict using iPSCs (Yagi et al., 2011). Strategies
such as accelerating the appearance of pathological phenotypes by
the exposure to disease stimulator effects (i.e., oxidative stressors,
hydrogen peroxide, MG-132 etc) as well as xenografting these
human iPSC-derived diseased-cells to generate humanized ani-
mals might overcome these iPSCs limitations (Kunkanjanawan
et al., 2011; Nguyen et al., 2011). Secondly, female hiPSCs poses an
extra challenge. Despite female organism consists of a mosaic for
X-inactivation, hiPSCs are clonal and all cells carry the same inac-
tivated X-chromosome (Tchieu et al., 2010; Mekhoubad et al.,
2012). Such limitation could be crucial for disease modeling
specially for X-linked diseases.
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Even if considering its limitations, iPSCs represents a prac-
tical system that simplifies diseases to fundamental aspects and
complements biochemical and animal-based drug development
by avoiding expenses with human-ineffective or toxic medicines.
CONCLUSION
Low-level random aneuploidy (mainly chromosomal losses) has
been described as a natural phenomenon in the human brain,
however; because chromosomal losses and gains have been
observed at higher frequencies in some brain pathologies, an ane-
uploidy frequency limit and/or chromosomal-specific aneuploidy
type separating healthy from diseased brains seems to exist.
In order for iPSCs to be safely used as a cell repository for
damaged or deteriorating tissue, as well as being able to mod-
eling aspects of any given disease, they must retain the original
tissue characteristics. Like PSCs, self-renewable NPCs also gener-
ate low-level aneuploidy in CNS. We believe chronic exposure to
stressing environments related to complex predisposing genetic
background could enhance aneuploidy generation in diseased-
brains, which in turn could prevent defective cells clearance and
participate in pathophysiology.
Aneuploidy’s recurrent descriptions in PSCs raised the con-
cern that these cells would not be appropriate for transplant
or reliably model diseases. Observation that PSCs exhibit lax
checkpoints and mostly exist as stochastic chromosomal mosaics,
added to the fact that some normal tissues, including the brain,
display this same pattern, suggest mosaic aneuploidy is intrinsic
to these cells. Even more, both NPCs and PSCs share self-renewal
capacity, suggesting random low-level aneuploidy could be linked
to this characteristic. A stochastic process implies that random
(advantageous, detrimental and neutral) aneuploidies must exist.
However, in nature, diversity generation comes at a price: the
samemechanism responsible for conferring organisms with more
adaptability to adverse environment can generate dysfunction.
Althoughmany harmful chromosomal imbalances can direct cells
to apoptosis, some could generate viable impaired cells resis-
tant to cell death, resulting in biased differentiation capacities.
Therefore, PSCs envisaged for transplant use should have their
genome thoroughly examined for the presence of certain ane-
uploidies already associated to specific phenotypes in mosaic
tissues and cancers. More studies need to be undertaken aiming
comprehensive classification of pathogenic aneuploidies.
Mixing distinct proportions of aneuploid and euploid cells
could also help to elucidate if a maximum aneuploidy limit is
required to warrant healthy tissue physiology. In spite of its
limitations, iPSCs still seem to provide a valid, easy to use,
patient-specific model complementary to its animal and bio-
chemical (purified receptor-based) counterparts, able to uncover
aspects of poorly understood diseases and accelerate personal-
ized and efficient drug choice/development. Moreover, provided
these pluripotent cells are scrutinized for pathogenic-associated
genomic instability, they could even serve in the future to treat
neurodegenerative diseases in a cell-transplant manner.
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